Industry Reports

Structural Pricing Pressure is Reshaping Pharma in 2026

Yuvraj — Thu, 19 Mar 2026 13:14:37 +0000

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

The post Structural Pricing Pressure is Reshaping Pharma in 2026 first appeared on World Pharma Today.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Yuvraj — Thu, 19 Mar 2026 13:07:41 +0000

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

The post Merck Targets $70B Revenue in 2026 with Cidara Deal first appeared on World Pharma Today.

U.S. Drug Pricing Reset Becomes Real in 2026

Yuvraj — Thu, 19 Mar 2026 11:50:06 +0000

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

The post U.S. Drug Pricing Reset Becomes Real in 2026 first appeared on World Pharma Today.

White House-Big Pharma Tariff and Pricing Deals in 2026

Yuvraj — Thu, 19 Mar 2026 11:42:06 +0000

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

The post White House-Big Pharma Tariff and Pricing Deals in 2026 first appeared on World Pharma Today.

GSK, Amgen and Others Restart the Pharma M&A Engine in 2026

Yuvraj — Thu, 19 Mar 2026 11:15:51 +0000

In 2026, GSK, Amgen and other large pharma players restarted the M&A engine with targeted deals in immunology and oncology, signalling a shift toward science‑driven, portfolio‑balancing acquisitions. Explore how this new M&A cycle is reshaping the global pharma landscape.

The post GSK, Amgen and Others Restart the Pharma M&A Engine in 2026 first appeared on World Pharma Today.

Global Pharma Pricing Shocks in West Drive Asia Growth

Yuvraj — Thu, 19 Mar 2026 10:59:20 +0000

Global pharma in Q1‑2026 is defined by pricing shocks in the US and Europe and a powerful growth shift to Asia. Explore how policy, margins, M&A and regional strategies are reshaping the pharmaceutical industry.

The post Global Pharma Pricing Shocks in West Drive Asia Growth first appeared on World Pharma Today.

Weight-Loss Pills Mark a Turning Point for Pharma Industry

Yuvraj — Mon, 16 Feb 2026 11:58:02 +0000

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive pressures in one of the fastest-growing drug categories. The commercial success of GLP-1 receptor agonists such […]

The post Weight-Loss Pills Mark a Turning Point for Pharma Industry first appeared on World Pharma Today.

Why Hospitals are Investing in Sustainable Healthcare to Protect Patients and Environment?

Yuvraj — Tue, 27 Jan 2026 09:36:53 +0000

Over more than ten years working in healthcare, medical manufacturing, and life sciences, it’s clear how much the industry has developed and adapted. One of the biggest shifts has been the focus on sustainability. What used to be a secondary concern is now part of everyday decisions in hospitals, pharmaceutical companies, medical device manufacturers, and […]

The post Why Hospitals are Investing in Sustainable Healthcare to Protect Patients and Environment? first appeared on World Pharma Today.

Navigating Pre- and Post-Market Regulatory Obligations: Key Differences Between the US and EU

Yuvraj — Tue, 27 Jan 2026 08:05:23 +0000

Bringing a pharmaceutical product to market is hard work. Pre-market regulatory requirements in the United States and the European Union are well established and generally well understood by experienced development teams. And it still years and millions of dollars to ensure that clinical development, manufacturing controls, and marketing authorization submissions meet regulators’ expectations. What is […]

The post Navigating Pre- and Post-Market Regulatory Obligations: Key Differences Between the US and EU first appeared on World Pharma Today.

How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk?

Yuvraj — Wed, 14 Jan 2026 12:18:32 +0000

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how biotechnology impacts everyday lives. After more than a decade observing this market, I can confidently say […]

The post How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk? first appeared on World Pharma Today.